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Abstract
Background:    Although  the  role  of  the  osteoclast  in  bone  resorption  is  becoming  better
understood, much remains to be learned about osteoclastogenesis and the exact mechanism of
action of anti-resorbing agents such as 17β -estradiol. This study investigated bone and morphologic
osteoclast alterations following long-term estrogen administration to the B6D2F1 mouse. B6D2F1
mice aged 4-5 weeks were exposed to high levels of estrogen via implanted silastic tubing for at
least 12 weeks; controls received empty tubing. Femurs of control and treated mice were assessed
with radiology, quantitative histomorphometry and transmission electron microscopy.
Results:  After 8 weeks of treatment, there was radiologic evidence of severe osteosclerosis and
86% of femoral marrow space was replaced with bone. After 12 weeks histologic studies of treated
animals revealed that osteoclasts were positive for tartrate-resistant acid phosphatase but showed
markedly abnormal ultrastructure which prevented successful bone resorption.
Conclusions:  Findings extend our understanding of osteoclast structure and function in the
mouse  exposed  in  vivo  to  high  doses  of  estrogen.  Ultrastructural  examination  showed  that
osteoclasts from estrogen-treated mice were unable to seal against the bone surface and were
unable to form ruffled borders.
Background
Although the role of the osteoclast in bone resorption is
becoming better understood [1], much remains to be
learned about osteoclastogenesis and the exact mecha-
nism of action of anti-resorbing agents on the functional
osteoclast. The anti-resorbing agent 17β -estradiol is es-
pecially noteworthy because of the association of its de-
cline at menopause with the development of
postmenopausal osteoporosis. As previously noted by
Liu and Howard, the underlying cellular changes respon-
sible the increased bone formation which follows estro-
gen administration are still not well characterized [2].
In the present report we report findings on alterations in
osteoclast morphology following long term administra-
tion of high doses of 17β -estradiol to B6D2F1 mice. De-
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velopment of osteosclerosis and the disappearance of the
marrow space in these estrogen-treated mice is an inter-
esting and useful model since marrow stromal cells not
only contain the precursors for osteogenic cell lineages,
but they also exert important effects on osteoclastogene-
sis and lymphopoiesis, and modulate the effects of some
systemic factors of bone turnover. Osteoclasts, as well as
osteoblasts, possess estrogen receptors [3, 4, 5, 6]. He-
matopoietic cells also influence osteogenic cell differen-
tiation, and some evidence suggests that mature
lymphocytes influence osteoclast and osteoblast func-
tion. In the estrogen-treated mouse model used in the
studies reported here, natural killer (NK) cells, which
rely upon an intact bone marrow for full marrow matu-
ration, are arrested in a nonlytic state [7]; since marrow
space is lessened due to the osteosclerosis, the spleen
provides the source for T and B cells and macrophages.
The objective of the present study was to assess the func-
tional state of osteoclasts in estrogen-treated mice by de-
termining if osteoclasts retained tartrate-resistant acid
phosphatase activity (TRAP) and normal ultrastructural
features.
Results
Radiographic examination of excised specimens from
control and estradiol-treated mice confirmed the pres-
ence of osteosclerosis in the femurs of estradiol-treated
mice. Diaphyseal cortices were prominent in the mid-
shaft of control specimens (Figure 1A and 1C), but could
not be identified in specimens from estradiol-treated an-
imals (Figure 1B, 1D and 1E). These changes were not
due to differences in radiographic technique since con-
trol and estradiol-treated femurs shown in Figure 1 were
exposed side-by-side on the same film.
Figure 1
Radiographs of femurs from control (A and C) and estradiol-treated (B, D and E) mice. In control femurs (A and
C), note that the marrow space and cortical margins are apparent but cannot be seen in specimens from estradiol-treated mice
(B, D and E). Femurs marked A and B, and those marked C, D and E were radiographed as a group on the same X-ray film
using one exposure to eliminate variability in exposure and development of the films.BMC Cell Biology (2001) 2:3 http://www.biomedcentral.com/1471-2121/2/3
Histologic examination also confirmed osteosclerotic
features in femurs from estradiol-treated mice. Speci-
mens from estradiol-treated mice contained only small
regions of bone marrow (Fig. 2B) in contrast to control
bones (Figure 2A). Since the normal, pre-estradiol treat-
ment endosteal margin could still be histologically iden-
tified on these specimens, specimens were evaluated
with quantitative histomorphometry by first measuring
the old, normal marrow area and then measuring the
small marrow cavity areas present at time of harvest. On
average 86% of mid-shaft marrow space was replaced by
bone in estradiol-treated mice at 8 weeks (p < 0.0001
control vs estradiol-treated).
Figure 2
Photomicrographs of decalcified (A and B) and methacrylate-embedded (C and D) femoral specimens. Cross-
sections of normal mice show a normal marrow cavity (Fig. 2A) which is in sharp contrast to the appearance of the cross-sec-
tion from an estradiol-treated mouse (Fig. 2B) in which only small islands of marrow are present. Localization of Ocl using tar-
trate-resistant acid phosphatase (TRAP) localization in metaphyseal bone from a normal mouse (Fig. 2C) and from an estradiol-
treated mouse (Fig. 2D). (Fig. 2A and 2B, H&E, X 43; Fig. 2C and 2D, TRAP, X 640).BMC Cell Biology (2001) 2:3 http://www.biomedcentral.com/1471-2121/2/3
Osteoclasts (Ocl) present in both control and estradiol-
treated mice showed positive localization of TRAP (Fig-
ure 2C). In contrast to the close apposition of Ocl to the
bone surface seen in control specimens, in estradiol-
treated animals Ocl extended away from the bone sur-
face with little bone contact (Figure 2D). In order to fur-
ther investigate this observation, transmission electron
microscopy was performed to examine the fine structure
of the Ocl in estradiol-treated and control specimens.
Figure 3A illustrates the normal ultrastructural appear-
ance of an Ocl from a control femur; note the normal ruf-
fled border and snug apposition of the Ocl to the bone
surface. Ocl from estradiol-treated animals, however,
frequently showed only one margin of the cell perimeter
involved with small areas of ruffed border formation,
with the remainder of the cell surface displaying a
smooth profile (Fig. 3B). Some Ocl from estradiol-treat-
ed animals had no ruffled borders in spite of the appear-
ance of some attempt to form sealing podosome regions
(Fig. 3C).
Discussion
The present study indicated that severe changes in Ocl
morphology are associated with the cells' inability to car-
ry out resorption in the osteosclerotic estradiol-treated
mouse. Although osteoclasts retained TRAP activity, ul-
trastructural alterations were identified in estradiol-
treated animals in both the sealing patterns of osteo-
clasts against the bone surface and in altered brush bor-
der morphology. Proper sealing of the osteoclast against
the bone surface and a functional brush border are two
ultrastructural components believed to be of major im-
portance in Ocl function. The ultrastructural alterations
identified in estrogen-treated mice were very likely the
cellular functional basis for the decreased resorption and
development of osteosclerosis in estrogen-treated mice.
Osteoclast function and ultrastructural morphology have
been shown to be highly responsive to anti-resorbing
agents such as ethane-1-hydroxy-1,1-diphosphonate
(EHDP) [8, 9], dichloromethylene diphosphanate
(Cl2MDP) [10], calcitonin [11,12,13], other anti-resorp-
tive agents, such as mithramycin [14], and to gallium ni-
trate [15].
Although histochemical TRAP localization provides an
accurate and sensitive histologic method for identifica-
tion of Ocl, understanding osteoclastogenesis and Ocl
function remain a challenging area of bone research. The
current understanding of Ocl function is that the Ocl
seals its perimeter along the bone surface by means of
the podosome [16, 17, 18] . Within this sealed margin,
projections from the cytoplasm form the ruffled border,
a specialized Ocl-extracellular space in which bone re-
sorption occurs. In the present study in the mouse, dif-
ferentiation of osteoclast progenitors appears to be
dependent on the direct interaction of bone marrow stro-
mal cells with Ocl precursor cells [19, 20]. Recent data of
Baylink [21] and Linkhart [22] provide evidence that two
inbred strains of mice with different bone densities may
have fundamental differences in bone resorption (not
bone formation), and that genes affecting the bone mar-
row Ocl precursor population may contribute to relative
differences in the C57BL/6J and C3H/HeJ strains. In
vivo and in vitro studies of avian osteoclasts led Pederson
et al to suggest that modulation of the Ocl response to es-
trogen may be controlled by alterations in the Ocl estro-
gen receptor level [3].
Maturation of osteoclasts from their macrophage pre-
cursors requires marrow stromal cells or their osteoblast
progeny as shown by Udagawa et al [23]. These cells pro-
duce macrophage colony-stimulating factor (M-CSF)
and the receptor for activation of nuclear factor kappa b
(NF-kB) (RANK) ligand (RANKL). M-CSF is essential for
macrophage maturation, but formation of osteoclasts
also requires contact between osteoclast precursors and
stromal cells or osteoblasts [23]. As described by Hof-
bauer et al [24], the quantity of bone resorbed depends
on the balance between expression of RANKL and of its
inhibitor, osteoprotegerin (OPG). Hofbauer et al suggest
that the stimulation of the pool of M-CSF precursors to
committed osteoclastogenesis by RANKL may be one of
the central pathophysiologic pathways involved in in-
creasing the number of osteoclasts in osteoporosis.
Futures studies of the estrogen-treated mouse model are
needed which are designed to address osteoclastogenesis
and osteoprotegerin (OPG) secretion by osteoblasts.
OPG is currently hypothesized to be an important para-
crine mediator of the antiresorptive action of estrogen on
bone cells [25]. In osteoblast cell lines exposed to estro-
gen, OPG mRNA and protein levels were increased com-
pared to controls. Hofbauer et al have suggested that
estrogen may exert its anti-resorptive effects by en-
hancement of OPG secretion by osteoblasts [11].
Future studies should also assess the temporal develop-
ment of functional changes in the osteoclast populations
during estrogen treatment, and the patterns of osteoclast
death with special attention to apoptosis. Estradiol has
been shown to modulate IL-1 action on human osteo-
clasts in vitro; estrogen administration inhibited IL-1-
mediated cytokine (IL-8) mRNA induction and caused
increased Ocl apoptosis [26]. When avian Ocl were ex-
posed to estradiol in vitro, the Ocl plasma membrane be-
came depolarized and there was a marked decrease in
potential, suggesting that estrogen may regulate osteo-
clasts through ion channel activities [27]. Estradiol has
also been shown to inhibit acid production in avian OclBMC Cell Biology (2001) 2:3 http://www.biomedcentral.com/1471-2121/2/3
Figure 3
Transmission electron micrographs of Ocl from control (Fig. 3A) and from estradiol-treated (Fig. 3B and 3C)
mice. Note the normal, extensive ruffled border present on the margin of an Ocl from a control femur (Fig. 3A). In estradiol
treated animals, Ocl show either very small portions of the cell perimeter involved with ruffled border formation and the
remainder of the cell surface reveals a smooth profile (Fig. 3B) or no ruffled border formation (Fig. 3C). (Fig. 3A, X 3,290; 3B,
X 1,310; 3C, X 4,230)BMC Cell Biology (2001) 2:3 http://www.biomedcentral.com/1471-2121/2/3
[28]. The human pre-Ocl cell line FLG 29.1 has specific
binding sites to 17β -estradiol on the cell surface, and es-
tradiol exposure increases the cellular pH, cAMP, cGMP
and intracellular calcium [29].
In vivo work by Jilka et al has shown that Il-6 can prevent
the bone loss associated with ovariectomy in the mouse
model [30]. Girasole et al have recently shown that pro-
duction of IL-6 is inhibited in vitro by exposure of mar-
row cells to 17β -estradiol; cultures of mouse bone cells
showed suppressed osteoclast development when ex-
posed to either 17β -estradiol or a neutralizing antibody
to Il-6 [31]. Future in vivo studies combining estradiol
and selected interleukins may further elucidate how the
network of signals from the marrow microenvironment
influences both Ocl development and Ocl function.
Conclusions
Findings extend our understanding of osteoclast struc-
ture and function in the mouse exposed in vivo to high
doses of estrogen. Ultrastructural examination showed
that osteoclasts from estrogen-treated mice were unable
to seal against the bone surface and were unable to form
ruffled borders.
Materials and Methods
B6D2F1 mice were selected for this study based upon the
following criteria. The C57BL/6 mouse is positive for the
NK 1.1 epitope but from previous unpublished data we
found that the C57BL/6 responded poorly to estradiol.
From previous hybrid resistance studies we had histori-
cal data that the B6D2F1 mouse would be positive for the
NK 1.1 epitope and respond well to the estradiol. B6D2F1
male mice aged 4-5 weeks were implanted for at least 12
weeks with silastic tubing filled with 15 mg 17β -estradiol
[32, 33, 34, 35]; age-matched controls received empty
tubing. NK cytolytic functions disappeared in estradiol-
treated mice by 8 weeks. Previous work with the model
by Roubinian et al showed that administration of 5-6.5
mg estradiol by this method returned estrogen levels to
normal in ovariectomized mice for more than 3 months
[36]. Seaman et al has also reported that administration
15 mg estradiol in this model was capable of raising es-
tradiol to 9 times the normal level [37, 38].
At 8-18 weeks post-implantation, euthanasia was per-
formed (CO2 inhalation) and femurs were harvested
from 13 control and 33 estradiol-treated mice. Cross-sec-
tions of the femur and sections of femoral metaphyses
and epiphyses were studied. For light microscopy, speci-
mens were either fixed in 10% neutral buffered formalin,
decalcified and embedded in paraffin or processed non-
decalcified and embedded in methyl methacrylate. For
ultrastructural studies, specimens were fixed in Kar-
novsky's fixative, post-fixed in osmium tetroxide, decal-
cified, and embedded in Spurr resin. Thin sections were
prepared and grids were stained with uranyl acetate and
lead citrate. Sections were viewed on a Phillips CM10
transmission electron microscope. Light microscopic
sections were evaluated with quantitative histomor-
phometry using OsteoMeasure software (OsteoMetrics,
Inc., Decatur, GA). Tartrate-resistant acid phosphatase
(TRAP) localization was performed to identify osteo-
clasts with light microscopy. Protocols were approved by
the appropriate Institutional Animal Care and Use Com-
mittee.
Statistical analysis of quantitative histomorphometric
data used standard statistical methods; means and
standard deviations were calculated. Unpaired t-tests
were used to test for differences between means; a p-val-
ue of <0.05 was considered statistically significant.
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